David Elsley

Cardiol Therapeutics Inc., (TSX: CRDL) (OTCQX: CRTPF) is focused on producing pharmaceutical cannabidiol (CBD) products for commercialization and to support the development of innovative therapies for heart diseases, including acute myocarditis and other causes of heart failure. The company's lead product, CardiolRx™, is pharmaceutically produced, manufactured under cGMP, and is THC free (<10 ppm). The company plans to commercialize CardiolRx in the billion-dollar market for medicinal cannabinoids in Canada.

Cardiol is planning a Phase 2 international trial of CardiolRx in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age. The company is also developing proprietary cannabidiol formulations for the treatment of inflammation in the heart that is associated with the development and progression of heart failure. Heart failure is the leading cause of death and hospitalization in North America, with associated annual healthcare costs in the US alone exceeding $30 billion. For further information about Cardiol Therapeutics, please visit www.cardiolrx.com.